600196 复星医药
2025/09 - 九个月
人民币(K¥)
2024/12
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
2021/12
人民币(K¥)
经营活动产生之现金流量净额3,381,7694,476,9813,414,2174,217,5713,937,815
投资活动产生之现金流量净额(1,511,832)(3,613,323)(3,819,290)(4,064,038)(3,857,489)
筹资活动产生之现金流量净额(3,244,427)(1,002,586)(1,336,250)4,428,475(819,407)
汇率变动对现金及现金等价物的影响(80,827)27,98973,645128,342(134,712)
现金及现金等价物净增加/(减少)(1,455,317)(110,939)(1,667,678)4,710,350(873,794)
期初现金及现金等价物余额9,391,4509,502,38911,170,0676,459,7177,333,511
期末现金及现金等价物余额7,936,1329,391,4509,502,38911,170,0676,459,717